Dr Reddy’s initiates EUA process with DCGI for Sputnik V

Dr Reddy’s Laboratories Ltd has initiated the process with the Drugs Controller General of India (DCGI) for emergency use authorization (EUA) of the well-studied human adenoviral vector-based platform vaccine candidate, Sputnik V. As part of the review process, Dr Reddy’s will present the safety profile of the phase 2 study, and interim data of the phase 3 study. The vaccine is currently undergoing the phase 3 clinical trial in India.